Arcadia Biosciences raises $2.1M via exercise of options at reduced price; issues new options

Arcadia Biosciences, Inc.

Gross proceeds of approx. $2.1M from exercise of 808,595 existing options at reduced price of $2.575/share.
Issued new unregistered options to purchase up to 1,617,190 shares at $2.325/share, expiring 30 months after resale registration effective date.
Existing options originally exercisable at $9.00/share; induced exercise by lowering price to $2.575.
Company to file resale registration statement for new option shares within 30 days of closing.
Net proceeds to be used for working capital and general corporate purposes.

item 1.01 item 3.02 item 3.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Arcadia Biosciences, Inc. entered into Inducement Letters with Participating Holders valued at Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options (effective 2026-01-09).

Action: entry
Agreement: equity purchase
Counterparty: Participating Holders
Value: Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options
Effective: 2026-01-09

Exact text from the filing

On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock ("Common Stock").

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-012028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.